Bank of America has upgraded Intel Corp. to Buy from Underperform, significantly raising its price target to $135 from $96. This positive outlook is driven by increased confidence in Intel's long-term CPU sales and contract manufacturing opportunities, with analysts projecting 2030 EPS power to exceed $6. Despite potential risks like intensifying competition and execution challenges, BofA sees Intel as undervalued given its institutional ownership and market capitalization.

James Schreiner, Executive Vice President & Chief Operating Officer of MKS Instruments, Inc., sold 781 shares of MKS Inc (MKSI) on June 10, 2026. After this transaction, Schreiner now holds 22,701.121 shares of the company. MKS Instruments is a global provider of instruments and process control solutions.

James Schreiner, COO of MKS INC (NASDAQ:MKSI), sold 781 shares of company stock for $247,905 on June 10, 2026, under a Rule 10b5-1 trading plan. This sale comes as MKSI shares are trading near their 52-week high after a significant gain, and the stock is considered overvalued according to InvestingPro analysis despite the company reporting strong Q1 2026 results and receiving an increased price target from Mizuho.

Hexcel Corporation is showcasing its composite solutions for the defense industry at Eurosatory, emphasizing lightweight, high-performance, and sovereign solutions. The company highlights its vertically integrated supply chain within Europe, ensuring industrial independence and combat-proven reliability for critical assets across various platforms like aircraft, rotorcraft, and space systems. Hexcel's advanced materials, including carbon fiber, honeycombs, and matrix systems, offer strength, thermal stability, and reduced maintenance costs for defense applications.

Laser Photonics Corporation (LASE) stock has surged by 16.27% due to positive developments in its laser technology applications. Key catalysts include the U.S. government selecting its Laser Shield Anti-Drone (LSAD) system for evaluation and a $250K order from Johnson & Johnson for a custom laser drilling system. Despite these advancements, LASE remains an early-stage, unprofitable company with a weak balance sheet, making it a speculative trading vehicle driven by catalysts rather than steady cash flow.

Enphase Energy receives a Hold rating due to weak near-term solar market fundamentals, high valuation, and significant projected earnings decline. While the company's pivot to AI data center transformers shows promise for future growth, commercial impact is not expected for several years. Enphase's strong balance sheet provides resilience, but its stock performance relies on solar market stabilization or new federal incentives.

L3Harris Technologies has secured a U.S. Army contract worth up to $106 million for its Vampire counter-unmanned aircraft systems. This award highlights the growing demand for drone defense mechanisms in the military. The Vampire system is noted for its rapid deployability, affordability, and proven effectiveness in combat operations.

Alphabet has significant investments in both SpaceX and Anthropic, making it an indirect way for investors to gain exposure to these innovative companies before their IPOs. Alphabet's initial $900 million investment in SpaceX over a decade ago now represents an approximate 6% stake in the trillion-dollar company, while a $3 billion investment provides a 14% stake in Anthropic, which recently confidentially filed for an IPO at a $965 billion valuation. Despite potential risks like antitrust issues and shareholder dilution, Alphabet's robust financials and stable position provide a less volatile investment option for those interested in the success of SpaceX and Anthropic.

Willis Towers Watson (WTW) is highlighted as one of Seth Klarman's non-AI stock picks, with his Baupost fund holding a $259 million stake. Despite a 20% stock drop due to AI disintermediation fears from the insurance brokerage sector, the article argues these concerns are overblown, especially for complex business insurance needs. The company has also successfully implemented AI internally to boost sales and reduce post-call reviews.

Abridge, an AI clinical assistant company, has secured a strategic investment from Eli Lilly and expanded its platform to integrate payer and life sciences workflows. The company aims to connect care delivery, payment, and evidence-based treatment, streamlining administrative tasks like billing, prior authorization, and clinical documentation. Abridge is also collaborating with organizations like Highmark Health, Availity, AHIMA, the American Diabetes Association, and the American Heart Association to enhance its offerings and improve patient outcomes.